As investors enter Samvat 2083, the landscape calls for selectivity rather than indiscriminate optimism. Global uncertainties, fluctuating capital flows and evolving market expectations continue to influence equity performance. In this environment, sustainable wealth creation is likely to depend less on broad-based market movements and more on identifying businesses capable of delivering consistent earnings growth. Here are 8 stocks Angel One is bullish on:
Angel One has set the target price at Rs 1,800, an upside of 14.5% from current market levels. The private lender is India's second-largest private-sector bank, with a market capitalisation of about Rs 10 lakh crore and a pan-India retail, SME and corporate franchise.
The brokerage has pegged the target price at Rs 330 per share, an upside of 16% from current levels. Analysts are optimistic based on 6.1x FY29E EPS of Rs 54 (about 1.0x FY29E book value; the stock trades at 4.5x). Angel One sees a score for sustained earnings compounding as lending AUM grows 20% a year to Rs 28,600 crore by FY29E and direct-to-customer lending lifts NIM towards 10%.
With a target price of Rs 1,160, the brokerage forecasts an upside of 25%. Aarti Pharmalabs is India’s largest manufacturer of xanthine derivatives (caffeine and allied products), with a 15–20% global market share. It has complete backward integration across its manufacturing value chain, with minimal reliance on Chinese imports.
With a target price of Rs 410, the brokerage predicts an upside of 50% from current levels. The analysts rate Shanti see scope for sustained volume-led compounding as new capacity (Marol and Jaipur) and new retail customers support 50–60% FY27 revenue growth.